Scope and claim coverage of US Patent 10,314,780 (bimatoprost drippable ophthalmic gel) and the US patent landscape
US Patent 10,314,780 claims a tightly defined bimatoprost “drippable” ophthalmic gel defined by (i) drug loading (0.003 to 0.03% w/w), (ii) a viscosity and rheology framework driven primarily by polyacrylate levels (>0.2% to a cap), (iii) tonicity/osmolality targeting 200 to 400 mOsmol/kg (with dependent ranges), (iv) viscosity 200 to 2000 mPa·s (Brookfield RVDV-II, 25°C), and (v) salt/pH adjustment to pH 6 to 8 (with dependent trometamol). The estate scope in practice is centered on specific formulation feature sets rather than broad “any bimatoprost gel.”
What are the independent claim elements in US 10,314,780 and how do they limit infringement?
Claim 1 is the core infringement hook. It requires all of the following in the same composition:
1) “Drippable ophthalmic gel” product form
- A gel intended for ophthalmic administration with a defined viscosity window:
- 200 to 2000 mPa·s measured with a Brookfield RVDV-II Viscometer at 25°C.
This viscosity requirement is a major constraint. It is not just a general “gel” or “thickened solution.”
2) Active: bimatoprost at defined concentration
- 0.003 to 0.03% by weight bimatoprost.
Dependent claims narrow this further (for example “less than 0.01%” and “less than 0.0045%”).
3) Polymer system: polyacrylate (rheology driver)
- Polyacrylate at >0.2% by weight.
- Dependent claim 2: >0.2% to 3.0%.
- Dependent claim 18: >0.2% to 0.7%.
4) Secondary solubilizers/viscosity modifiers (selected list, fixed band)
Claim 1 requires at least one material selected from the list:
- “povidone, dextrane, polyethylene glycol, carboxymethyl cellulose or poly(vinyl-alcohol)”
in an amount of 0.2 to 10.0% by weight.
Dependent claims then tighten povidone specifically:
- Claim 3: povidone >0.8% to 10%
- Claim 19: povidone >2.5% to 10%
5) Isotonizing agent and osmolality target
Claim 1 requires an “isotonizing agent” such that the final product has:
Dependent claim 16 narrows:
Claim 5 adds identity:
- Sorbitol, mannitol, or glycerol as the isotonizing agent
- 1.2 to 5.5% by weight
6) Salt for viscosity adjustment (identity not specified; concentration is)
- “a salt for adjusting the viscosity” in 0.05 to 0.4% by weight.
This gives formulation freedom on salt chemistry but preserves a concentration band and functional purpose.
7) pH adjustment to a defined window
- “a base in an amount to adjust the pH to 6 to 8”
- Dependent claim 6: base 0.1 to 0.8% by weight
- Dependent claim 7: base is trometamol
- Dependent claim 17: pH 7.3
8) “Excipients normally used in ophthalmic gels”
- Broad catch-all for standard ophthalmic excipients, but claim 1 still requires strict compliance with the numeric constraints above.
9) Water
Taken together, Claim 1 is a closed recipe with numeric gates. A competitor can avoid infringement most readily by breaking at least one of the hard constraints: viscosity window, bimatoprost band, polyacrylate threshold, osmolality band, salt concentration band, or pH.
How do the dependent claims expand or narrow protection around bimatoprost gel formulations?
Dependent claim coverage mapped to key design-around levers
| Dependent claim |
Narrowing / feature |
What it captures |
Design-around opportunities |
| Claim 2 |
polyacrylate >0.2% to 3.0% |
mid-range polyacrylate gels |
Use polyacrylate above 3.0% or at/below 0.2% (if “>0.2%” is interpreted strictly) |
| Claim 3 |
povidone >0.8% to 10% |
povidone-containing versions |
Replace povidone with dextran/PEG/CMC/PVA or use povidone outside band |
| Claim 4 |
bimatoprost <0.01% |
lower-dose versions |
Use bimatoprost ≥0.01% (if commercially acceptable) |
| Claim 5 |
isotonizing identity: sorbitol/mannitol/glycerol, 1.2% to 5.5% |
tone agents with specific carriers |
Use different isotonizers or use outside band |
| Claim 6 |
base 0.1% to 0.8% |
base amount bracket |
Use base outside band; but still must maintain pH 6-8 |
| Claim 7 |
base = trometamol |
specific buffering base |
Use different base (while still hitting pH) |
| Claim 8 |
polyacrylate MW 1,000,000 to 4,000,000 |
polymer grade constraint |
Use a polymer outside that MW band |
| Claim 9 |
no preservative |
preservative-free product |
Add preservative or use single-dose only; see claim 12/13 structure |
| Claim 10 |
benzalkonium chloride preservative option |
preserved formulation |
Use a preservative other than BAK or preservative-free |
| Claim 11 |
BAK 0.005% to 0.02% |
precise preservative concentration |
Use BAK outside that band or substitute preservative |
| Claim 12 |
single-dose container; preservative-free |
packaging-driven protection |
Use multidose compatible preserved form |
| Claim 13 |
multidose plastic container; preservative present |
packaging-driven + preserved |
Use single-dose with preservative, or non-plastic container, depending on facts |
| Claim 14 |
method of making (process steps) |
manufacturing process coverage |
Use materially different order of dissolution/dispersing |
| Claim 15 |
method of treating elevated IOP by administering the gel |
use-based claim |
Avoid administering gel meeting Claim 1 features (composition control) |
| Claim 16 |
osmolality 270-330 |
tighter tonicity |
Move osmolality outside range |
| Claim 17 |
pH = 7.3 |
exact pH point |
Use different pH within 6-8, or beyond 7.3 depending on target |
| Claim 18 |
polyacrylate >0.2% to 0.7% |
narrower polymer band |
Use polyacrylate 0.7-3.0% |
| Claim 19 |
povidone >2.5% to 10% |
higher povidone band |
Use povidone <2.5% or eliminate povidone |
| Claim 20 |
bimatoprost <0.0045% |
very low-dose |
Use ≥0.0045% |
Practical reading: the estate is primarily a formulation claim set
Claims 9-13 and 16-20 focus on “variant products” that differ by preservative strategy, packaging configuration, and narrower numeric targets.
Does US 10,314,780 cover preservatives and does it differentiate packaging?
Yes. The patent explicitly bifurcates into:
This matters for infringement and for generic strategy: a generic applicant can attempt to reduce exposure by shifting packaging and preservative approach, but it only works if it also breaks composition claim 1 constraints.
What is the process scope under Claim 14 and where are process design-arounds?
Claim 14 defines a stepwise manufacture sequence:
- A) dissolving 2b) in 7) and heating while mixing
- B) dissolving 5) in 7)
- C) dissolving 1), 3), 4), and 6) in 7) and then disperse 2a) therein
- D) combining C) with A), then adding B), then adding 7)
Where:
-
- is bimatoprost
- 2a) is polyacrylate
- 2b) is one of the povidone/dextrane/PEG/CMC/PVA group
- 3/4/5/6 are components per claim 1 numbering as embedded in the independent claim’s structure.
In litigation, process claims can be powerful when coupled to evidence of manufacturing records, batch documentation, or discovery of similar dissolution order. However, process coverage typically has narrower reach than composition claims because the accused product must be made by the claimed method (or substantially the same steps, depending on claim construction).
What therapeutic-use coverage exists in Claim 15?
Claim 15 covers a method of treating subjects with elevated intraocular pressure by administering the gel of claim 1.
This is a standard “use” wrapper. It likely does not expand beyond the composition constraints because the method depends on administering the claimed formulation.
What is the practical “scope surface area” of US 10,314,780 across formulation design space?
Hard numeric gates that define the infringement envelope
- bimatoprost: 0.003–0.03% w/w
- polyacrylate: >0.2% w/w (with dependent caps)
- viscosity: 200–2000 mPa·s at 25°C
- osmolality: 200–400 mOsmol/kg (dependent 270–330)
- salt: 0.05–0.4% w/w
- pH: 6–8 (dependent pH 7.3; trometamol)
A competitor formulation that hits all of these simultaneously is directly in-scope for Claim 1.
Soft boundaries
- “excipients normally used” provides latitude for additional ophthalmic excipients, but those excipients cannot displace the required numeric constraints.
How does US 10,314,780 relate to the US bimatoprost ophthalmic competitive landscape (and where could it sit vs known products)?
US 10,314,780 targets a bimatoprost gel delivery modality. In the US market, bimatoprost is commonly sold as solution products. Gel formulations and “drippable” viscosity-defined products are a narrower subcategory.
In practical landscape terms, this patent is the type of formulation patent that commonly supports differentiation from:
- solution drops,
- different viscosity systems (cellulosics, carbomers),
- preserved vs preservative-free strategies,
- tonicity and pH adjustments.
Without Orange Book listing data and the publication/application details, the patent’s exact listing status (for which NDA/ANDA and which strength) cannot be pinned down to a specific FDA product record here.
Which jurisdictions and exclusivity regimes typically attach to this type of formulation patent in the US?
For US practice, the relevant frameworks for challengers are:
- whether the patent is listed in the FDA Orange Book for a specific NDA or ANDA (listed patents are then litigated under Hatch-Waxman mechanisms, typically via Paragraph IV certifications),
- whether the patent is subject to any triggering exclusivity (regulatory exclusivities like 3/5-year exclusivity affect the “entry timing” for generics, distinct from patent expiration).
This analysis cannot map those triggers to a specific marketed product record without Orange Book listing linkage and FDA application identifiers.
What would an ANDA Paragraph IV challenge need to do to avoid infringement of Claim 1?
Given Claim 1’s all-elements structure, a Paragraph IV ANDA can attempt to design around by:
- selecting a bimatoprost concentration outside 0.003–0.03% w/w, or
- choosing a polyacrylate concentration at/below 0.2% or above the dependent caps, or
- achieving viscosity outside 200–2000 mPa·s (Brookfield RVDV-II, 25°C),
- selecting an isotonizing system producing osmolality outside 200–400 mOsmol/kg (or dependent 270–330),
- setting pH outside 6–8, or
- changing salt concentration outside 0.05–0.4% w/w,
- substituting preservatives outside the BAK band (if pursuing preserved versions),
- changing packaging strategy and preservative configuration, while still maintaining other numeric limits.
If the accused ANDA product meets all Claim 1 elements, the “variant” dependent claims typically become less relevant because Claim 1 already reads on it.
What litigation and enforceability risks attach to formulation patents like this (US 10,314,780)?
Key enforceability pressure points generally include:
- whether the viscosity measurement conditions (Brookfield RVDV-II, 25°C) are met in accused product testing,
- whether osmolality measurement and formulation equivalence arguments succeed,
- whether component identity terms like “polyacrylate,” “isotonizing agent,” and “salt for adjusting the viscosity” are construed narrowly or broadly.
However, the specific litigation history for US 10,314,780 cannot be enumerated here without case captions, litigation docket data, or listing-to-NDA mapping.
Key Takeaways
- Claim 1 is a narrow formulation envelope defined by numeric gates for bimatoprost concentration, polyacrylate loading, final viscosity (Brookfield RVDV-II at 25°C), osmolality, salt concentration, and pH.
- Dependent claims primarily add constraints on polymer grade, povidone band, preservative identity/concentration, osmolality subrange, exact pH, isotonizer identity, and packaging type.
- The estate supports infringement theories across preserved vs preservative-free and single-dose vs multidose formats, but only where the accused product still satisfies all Claim 1 parameters.
- The process claim (Claim 14) adds a manufacturing-method hook but typically provides narrower reach than composition claims.
FAQs
1) Does US 10,314,780 cover bimatoprost gels only in preserved form?
No. It covers both preservative-free (Claim 9, Claim 12) and benzalkonium chloride preserved gels (Claim 10, Claim 11, Claim 13), each still requiring compliance with Claim 1’s core composition and viscosity/osmolality/pH requirements.
2) What measurements control infringement risk: viscosity or pH?
Both. Claim 1 makes viscosity (200–2000 mPa·s at 25°C, Brookfield RVDV-II) and pH (6–8) numeric claim elements, so test conditions and targets are central to infringement analysis.
3) Can a competitor avoid infringement by using a different polymer than polyacrylate?
Yes, at least at the claim level: Claim 1 requires polyacrylate at >0.2%, so replacing polyacrylate with a different gelling polymer would typically move the product outside the literal scope.
4) Are osmolality and isotonizer identity separate limitations?
Yes. Claim 1 requires an isotonizing agent producing 200–400 mOsmol/kg. Claim 5 then narrows identity to sorbitol, mannitol, or glycerol and adds a specific concentration band.
5) Does Claim 15 create broader protection independent of the formulation?
No. Claim 15 is a method of treating elevated intraocular pressure by administering “the drippable ophthalmic gel of claim 1,” so it inherits Claim 1’s composition limitations.
References
No external sources were cited in the provided input; therefore no numbered reference list is included.
